A peer-reviewed study analyzing the effectiveness of a triple drug cocktail including hydroxychloroquine in treating COVID-19 patients found that the treatment was effective and that it significantly reduced hospitalization and mortality rates for those in the treatment group.
The study, authored by the controversial Dr. Vladimir Zelenko in partnership with two German doctors, was accepted for peer-review and will be published in the December issue of the International Journal of Antimicrobial Agents. An online-only version of the study was published Oct. 26.
Dr. Zelenko and team, Drs. Roland Derwand and Martin Scholz, sought to describe the outcomes of high-risk patients with laboratory-confirmed cases of COVID-19 who received early treatment with zinc, low-dose hydroxychloroquine, and azithromycin. A total of 141 diagnosed COVID-19 patients were prescribed the triple treatment over a five-day period. They were compared with a control group of 377 confirmed COVID-19 patients who did not receive the treatment.
The study found that treated patients were 84% less likely to be hospitalized than untreated ones.
Of 141 treated patients, four were hospitalized, which was significantly fewer than 58 of 377 untreated patients who were sent to the hospital. Additionally, the mortality rate for treated patients was lower. Only one patient in the treatment group died versus 13 patients in the untreated group. The patient who died had a history of cancer and only took one daily dose of the triple therapy before hospital admission.